In this double-masked study , patients were randomised to : 0.5 mg IVT-AFL every 4weeks ( 0.5 q4 ) ; 2mg IVT-AFL every 4weeks ( 2q4 ) ; 2mg IVT-AFL every 8weeks ( 2q8 ) after 3 monthly injections ; or 0.5 mg ranibizumab every 4weeks ( Rq4 ) .